News articles about Sienna Biopharm (NASDAQ:SNNA) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sienna Biopharm earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 49.1323937085711 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Sienna Biopharm (NASDAQ SNNA) traded up 1.73% during trading on Friday, hitting $19.38. The stock had a trading volume of 76,768 shares. Sienna Biopharm has a 12-month low of $18.50 and a 12-month high of $21.20.
In other news, Director Keith R. Leonard acquired 16,700 shares of the stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $250,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Timothy K. Andrews acquired 15,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were purchased at an average price of $15.00 per share, with a total value of $225,000.00. Following the completion of the transaction, the general counsel now owns 51,737 shares of the company’s stock, valued at $776,055. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 48,700 shares of company stock valued at $730,500.
Sienna Biopharm Company Profile
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with our FREE daily email newsletter.